Waldenstroms macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F17%3A00111963" target="_blank" >RIV/00216224:14310/17:00111963 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/17:A1801QUJ RIV/00843989:_____/17:E0106661 RIV/65269705:_____/17:00075968

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12959" target="_blank" >https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12959</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.12959" target="_blank" >10.1111/ejh.12959</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Waldenstroms macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

Popis výsledku v původním jazyce

Waldenstroms macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.

Název v anglickém jazyce

Waldenstroms macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

Popis výsledku anglicky

Waldenstroms macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

1600-0609

Svazek periodika

99

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

469-478

Kód UT WoS článku

000416145400001

EID výsledku v databázi Scopus

2-s2.0-85031129649